Radium-223 for patients with castration resistant prostate cancer with bone metastases a review of clinical effectiveness, cost-effectiveness and guidelines
The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC)
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 31 October 2016
|
Series: | Rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC) |
---|---|
Item Description: | "CADTH Rapid Response Service." |
Physical Description: | 1 PDF file (29 pages) illustrations |